Briefing
Circulating Tumor DNA Clearance Is Associated with Response and Survival in Metastatic Urothelial Carcinoma Treated with First-Line Enfortumab Vedotin Plus Pembrolizumab
In this single-center retrospective study of 25 patients with metastatic urothelial carcinoma treated with first-line enfortumab vedotin plus pembrolizumab, a tumor-informed assay (Signatera) measured ctDNA over time. Fifteen of 25 patients (60%) achieved ctDNA clearance (ever undetectable); the objective response rate was 76% overall and 100% (15/15) with clearance versus 40% (4/10) without (p = 0.0012). Clearance was associated with longer PFS (HR 0.16, 95% CI 0.05–0.54; p = 0.003) and OS (HR 0.08, 95% CI 0.01–0.68; p = 0.021), although these associations were attenuated in a time-dependent analysis (PFS HR 0.35, 95% CI 0.09–1.15, p = 0.085; OS HR 0.14, 95% CI 0.01–0.84, p = 0.029).